Emyria has launched a second ultra-pure CBD dose with a phase one clinical trial expected to begin later this year.

The company said EMD-RX7 will target indications that respond to high doses of CBD “as guided by Emyria’s extensive real-world data gathered with 6,000 patients”.

It said the dose demonstrated four times the bioavailability of Epidyolex in a pharmacokinetic animal study.

Dr Michael Winlo

EMD-RX7 will be the second Emyria CBD product being advanced towards registration with the Therapeutic Goods Administration and the US Food and Drug Administration.

Unlike EMD-RX5, which Emyria is looking to register as an over-the-counter schedule 3 product, the higher dosage of EMD-RX7 will remain prescription only.

Emyria managing director Dr Michael Winlo said: “Emyria’s real-world data suggests there are a range of clinical indications that respond to high daily CBD doses.

“We also know that most CBD available to patients has poor bioavailability, meaning only a small amount of active medicine enters the bloodstream where it can be effective. This is why we have developed a range of convenient, ultra-pure CBD capsules with improved bioavailability.

“With EMD-RX7 we have a convenient dose form that we believe can deliver higher CBD exposures more efficiently, allowing us to target a range of prescription-only indications. In other words, help the broad range of major unmet needs that affect the patients we treat every day at our clinical service subsidiary, Emerald Clinics.”     

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...